Abstract:<p></p><p>Phosphodiesterases(PDEs) are vital in signal transduction, specificallyby hydrolyzing cAMP and cGMP. Within the PDE family, PDE10A is notablefor its prominence in the striatum and its regulatory function overneurotransmitters in medium-spiny neurons. Given the dopamine deficiencyin Parkinson’s disease (PD) that affects striatal pathways,PDE10A inhibitors could offer therapeutic benefits by modulating D1and D2 receptor signaling. This study was motivated by the successfulhistory of quinazoline/quinazoline scaffolds in the inhibition ofPDE10A. This study involved detailed in silico evaluationsthrough docking followed by pharmacological, pharmacophoric, and pharmacokineticanalyses, prioritizing central nervous system (CNS)-active drug criteria.Seven cyclic peptides, those featuring the quinazoline/quinazolinemoiety at both termini, exhibited notably enhanced docking scorescompared to those of the remaining alkaloids within the screened library.We identified 7 quinolines and 1 quinazoline including Lepadin G,Aspernigerin, CJ-13536, Aurachin A, 2-Undecyl-4(1H)-quinolone, Huajiaosimuline 3-Prenyl-4-prenyloxyquinolin-2-one,and Isaindigotone that followed the standard CNS active drug criteria.The dominant quinoline ring in our study and its related quinazolinewere central to our evaluations; therefore, the pharmacophoric featuresof these scaffolds were highlighted. The top alkaloids met all CNS-activedrug properties; while nonmutagenic and without PAINS alerts, manyindicated potential hepatotoxicity. Among the compounds, Huajiaosimulinewas particularly significant due to its alignment with lead-likenessand CNS-active criteria. Aspernigerin demonstrated its affinity fornumerous dopamine receptors, which signifies its potential to alterdopaminergic neurotransmission that is directly related to PD. Interestingly,the majority of these alkaloids had biological targets primarily associatedwith G protein-coupled receptors, critical in PD pathophysiology.They exhibit superior excretion parameters and toxicity end-pointscompared to the standard. Notably, selected alkaloids demonstratedstability in the binding pocket of PDE10A according to the moleculardynamic simulation results. Our findings emphasize the potential ofthese alkaloids as PDE10A inhibitors. Further experimental studiesmay be necessary to confirm their actual potency in inhibiting PDE10Abefore exploring their therapeutic potential in PD.</p>

X-ray Structure-Guided Discovery of a Potent Benzimidazole Glutaminyl Cyclase Inhibitor That Shows Activity in a Parkinson's Disease Mouse Model

Discovery of a Potent Chloroacetamide GPX4 Inhibitor with Bioavailability to Enable Target Engagement in Mice, a Potential Tool Compound for Inducing Ferroptosis in Vivo.

Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design

Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives As Potent and Selective P21-Activated Kinase 4 (PAK4) Inhibitors

Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease

Glutaminyl cyclases, the potential targets of cancer and neurodegenerative diseases

Design, synthesis and anti-AD effects of dual inhibitor targeting glutaminyl cyclase/GSK-3β

Glutaminyl cyclase inhibitor contributes to the regulation of HSP70, HSP90, actin, and ribosome on gene and protein levels in vitro

Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site

Glutaminyl Cyclase, Diseases, and Development of Glutaminyl Cyclase Inhibitors

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Discovery of 2-(cyclopropanecarboxamido)-N-(5-((1-(4-fluorobenzyl)piperidin-4-yl)methoxy)pyridin-3-yl)isonicotinamide as a potent dual AChE/GSK3β inhibitor for the treatment of Alzheimer's disease: Significantly increasing the level of acetylcholine in the brain without affecting that in intestine

Synthesis and Preliminary Studies of a Novel Negative Allosteric Modulator, 7-((2,5-Dioxopyrrolidin-1-yl)methyl)-4-(2-fluoro-4-[11C]methoxyphenyl) quinoline-2-carboxamide, for Imaging of Metabotropic Glutamate Receptor 2

Inhibitory effect of flavonoids on human glutaminyl cyclase

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3β (GSK-3β) inhibitors

Identification of Novel Quinolone and Quinazoline Alkaloids as Phosphodiesterase 10A Inhibitors for Parkinson’s Disease through a Computational Approach

Discovery and Optimization of Tetrahydroisoquinoline Derivatives To Enhance Lysosome Biogenesis as Preclinical Candidates for the Treatment of Alzheimer's Disease

Development of a potent benzonitrile-based inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL) with antitumor efficacy

Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II

Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer’s disease